In a new report, Decision Resources Group (DRG) experts have highlighted four medtech innovations that they see tearing up the script.
The company is bracing for a $25 million revenue hit after FDA ordered two of its mesh products off the market, but a bigger concern may be lying in wait.
FDA has ordered Boston Scientific and Coloplast to stop selling surgical mesh intended for transvaginal repair of pelvic organ prolapse. Patient advocates say the action was not made soon enough and does not go far enough, but it is a step in the right direction.
Intervention Insights' new platform, Trapelo, was designed to resolve the complexities of precision medicine in real time.
Roughly 28,000 new Bivona tracheostomy tubes manufactured by Smiths Medical are currently awaiting sterilization.
FDA-mandated studies indicate higher than expected levels of contamination on duodenoscopes after reprocessing.
We’ve gathered our best advice from medical device experts to help you nail your next project or business milestone.
Competition for AI talent is white hot. So how can medtech companies differentiate themselves to snag the best AI engineers?
FDA warns the public not to use devices or apps marketed to consumers that claim to help assess, diagnose, or manage head injuries.
Parents of kids with tracheostomy tubes are unable to get new tubes due to a shortage that is the direct result of a recent sterilization plant being shut down by the Illinois EPA.
France banned several types of textured breast implants Friday as a precautionary measure. The implants are suspected of causing a rare form of cancer.
Silk Road Medical CEO Erica Rogers performed one of her legendary cartwheels Thursday during the company's closing bell ceremony. The company's IPO shot up 81% on its opening day, raising $120 million.
Mayo Clinic has been selected as a trial site for Physeon's U.S. trial for the Veinplicity. The device is designed to make veins easier to access on the first stick, preventing patients from being pincushions.
Friday marks Scott Gottlieb's final day as FDA commissioner. Here is a review of the key regulatory milestones and controversies that occurred during his time as the agency's 23rd commissioner.